CA2164837A1 - Compositions therapeutiques et methodes d'utilisation - Google Patents
Compositions therapeutiques et methodes d'utilisationInfo
- Publication number
- CA2164837A1 CA2164837A1 CA 2164837 CA2164837A CA2164837A1 CA 2164837 A1 CA2164837 A1 CA 2164837A1 CA 2164837 CA2164837 CA 2164837 CA 2164837 A CA2164837 A CA 2164837A CA 2164837 A1 CA2164837 A1 CA 2164837A1
- Authority
- CA
- Canada
- Prior art keywords
- weight
- parts
- acid
- component
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 title claims description 27
- 230000001225 therapeutic effect Effects 0.000 title description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 38
- 239000001124 (E)-prop-1-ene-1,2,3-tricarboxylic acid Substances 0.000 claims abstract description 19
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims abstract description 19
- 229940091181 aconitic acid Drugs 0.000 claims abstract description 19
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims abstract description 19
- GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 claims abstract description 19
- 239000001530 fumaric acid Substances 0.000 claims abstract description 19
- 239000001630 malic acid Substances 0.000 claims abstract description 19
- 235000011090 malic acid Nutrition 0.000 claims abstract description 19
- GTZCVFVGUGFEME-UHFFFAOYSA-N trans-aconitic acid Natural products OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 claims abstract description 19
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 19
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 claims abstract description 17
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000004334 sorbic acid Substances 0.000 claims abstract description 17
- 235000010199 sorbic acid Nutrition 0.000 claims abstract description 17
- 229940075582 sorbic acid Drugs 0.000 claims abstract description 17
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 claims abstract description 17
- 208000010444 Acidosis Diseases 0.000 claims abstract description 12
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 12
- 208000026545 acidosis disease Diseases 0.000 claims abstract description 11
- 230000007950 acidosis Effects 0.000 claims abstract description 9
- 206010017533 Fungal infection Diseases 0.000 claims abstract description 7
- 208000031888 Mycoses Diseases 0.000 claims abstract description 7
- 208000036142 Viral infection Diseases 0.000 claims abstract description 6
- 230000009385 viral infection Effects 0.000 claims abstract description 5
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 4
- 238000011282 treatment Methods 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 15
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 208000006454 hepatitis Diseases 0.000 claims description 7
- 231100000283 hepatitis Toxicity 0.000 claims description 5
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 230000000843 anti-fungal effect Effects 0.000 claims description 3
- 230000000840 anti-viral effect Effects 0.000 claims description 3
- 241000222122 Candida albicans Species 0.000 claims description 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 230000001512 anti-cytomegaloviral effect Effects 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 229940095731 candida albicans Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 abstract description 6
- 230000001575 pathological effect Effects 0.000 abstract description 4
- 235000011087 fumaric acid Nutrition 0.000 abstract 1
- 239000002253 acid Substances 0.000 description 16
- 210000002700 urine Anatomy 0.000 description 11
- 241000701022 Cytomegalovirus Species 0.000 description 10
- 241000700605 Viruses Species 0.000 description 9
- 150000007513 acids Chemical class 0.000 description 9
- 230000000120 cytopathologic effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 150000007524 organic acids Chemical class 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000007758 minimum essential medium Substances 0.000 description 5
- 235000005985 organic acids Nutrition 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000645 desinfectant Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010034038 Parotitis Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000002574 cystoscopy Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical class OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- LZENMJMJWQSSNJ-UHFFFAOYSA-N 3H-1,2-dithiole-3-thione Chemical class S=C1C=CSS1 LZENMJMJWQSSNJ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000019932 Aciduria Diseases 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 240000002129 Malva sylvestris Species 0.000 description 1
- 235000006770 Malva sylvestris Nutrition 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 206010049082 Pancreatic mass Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 206010050662 Prostate infection Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 1
- 240000005481 Salvia hispanica Species 0.000 description 1
- 235000001498 Salvia hispanica Nutrition 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000003113 alkalizing effect Effects 0.000 description 1
- 229920000180 alkyd Polymers 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000014167 chia Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 201000001494 papillary transitional carcinoma Diseases 0.000 description 1
- 208000031101 papillary transitional cell carcinoma Diseases 0.000 description 1
- 210000003681 parotid gland Anatomy 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000036412 respiratory physiology Effects 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- -1 tertiary amine ester Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 229940117958 vinyl acetate Drugs 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne un mélange d'acide sorbique, d'acide malique, d'acide fumarique, d'acide crotonique et, éventuellement, d'acide aconitique. La présente invention concerne également des procédés pour le traitement de divers états pathologiques, tels que les infections virales, l'acidose, les tumeurs et les infections bactériennes et fongiques par administration de quantités thérapeutiquement efficaces d'un mélange décrit ci-dessus.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7393493A | 1993-06-08 | 1993-06-08 | |
| US073,934 | 1993-06-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2164837A1 true CA2164837A1 (fr) | 1994-12-22 |
Family
ID=22116689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2164837 Abandoned CA2164837A1 (fr) | 1993-06-08 | 1994-06-08 | Compositions therapeutiques et methodes d'utilisation |
Country Status (5)
| Country | Link |
|---|---|
| AU (1) | AU7060394A (fr) |
| CA (1) | CA2164837A1 (fr) |
| DE (1) | DE4494231T1 (fr) |
| GB (1) | GB2294637B (fr) |
| WO (1) | WO1994028883A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1785799A (en) * | 1998-01-30 | 1999-08-16 | Ivan Gorgiev | Anticancer composition |
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| AUPP839499A0 (en) | 1999-01-29 | 1999-02-25 | Australian National University, The | A method for controlling plant pathogens, and agents useful for same |
| DE10000577A1 (de) | 2000-01-10 | 2001-07-26 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten |
| HU230252B1 (hu) | 2001-01-12 | 2015-11-30 | Biogen Idec International Gmbh | Fumársav-amid származékok |
| DE10101307A1 (de) * | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
| DE10217314A1 (de) | 2002-04-18 | 2003-11-13 | Fumapharm Ag Muri | Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere |
| SI1663197T1 (sl) | 2003-09-09 | 2008-06-30 | Biogen Idec Internat Gmbh | Uporaba derivatov fumarne kisline za zdravljenje sräśne insuficience in astme |
| EP2680006A1 (fr) | 2007-02-08 | 2014-01-01 | Biogen Idec MA Inc. | Essais de criblage de NRF2 et procédés et compositions correspondants |
| CN120435294A (zh) * | 2022-12-16 | 2025-08-05 | 图尔大学 | 用于治疗肺部病毒感染的乌头酸 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4828912A (en) * | 1981-07-20 | 1989-05-09 | Kimberly-Clark Corporation | Virucidal product having virucidal and/or germicidal properties |
-
1994
- 1994-06-08 CA CA 2164837 patent/CA2164837A1/fr not_active Abandoned
- 1994-06-08 GB GB9525254A patent/GB2294637B/en not_active Expired - Fee Related
- 1994-06-08 AU AU70603/94A patent/AU7060394A/en not_active Abandoned
- 1994-06-08 WO PCT/US1994/006653 patent/WO1994028883A1/fr not_active Ceased
- 1994-06-08 DE DE4494231T patent/DE4494231T1/de not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| GB9525254D0 (en) | 1996-02-21 |
| AU7060394A (en) | 1995-01-03 |
| GB2294637A (en) | 1996-05-08 |
| GB2294637B (en) | 1997-11-12 |
| DE4494231T1 (de) | 1996-10-17 |
| WO1994028883A1 (fr) | 1994-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5684045A (en) | Method of treating pancreatic atrophy | |
| US5397803A (en) | Use of glutamine to reduce rate of pathogenic microorganism infection | |
| Ershoff | Conditioning factors in nutritional disease | |
| US20010000028A1 (en) | Composition and method for treating nonalcoholic steatohepatitis | |
| KR20070092095A (ko) | 소독용 조성물 및 이의 제조 및 이용 방법 | |
| CA2164837A1 (fr) | Compositions therapeutiques et methodes d'utilisation | |
| US6066670A (en) | Therapeutic compositions and methods of use | |
| JP2002515410A (ja) | 広域スペクトルの殺菌用及び殺精子用の組成物、装置、及び方法 | |
| WO2024193100A1 (fr) | Lactiplantibacillus plantarum pour soulager l'hyperuricémie, complexe le comprenant et son utilisation | |
| Monafo et al. | 'Lethal'Burns: A Progress Report | |
| De Koning et al. | Combination therapy for dendritic keratitis with human leucocyte interferon and trifluorothymidine | |
| Lane et al. | The rapid induction of human riboflavin deficiency with galactoflavin | |
| Salisbury et al. | Apparent free amino acids in deproteinized plasma of normal and uremic persons | |
| AU7943794A (en) | Flavin derivatives as anti-viral agents | |
| KR20070048170A (ko) | 젖산 및 락토페린을 포함하는 조성물 | |
| Potter et al. | The Riboflavin Requirement of the Dog: Two Figures | |
| JP2972343B2 (ja) | スッポンとカメの組成物 | |
| Victor et al. | Pyomyositis in a patient with the acquired immunodeficiency syndrome | |
| SU1722502A1 (ru) | Препарат биоспорин дл профилактики и лечени желудочно-кишечных заболеваний человека | |
| EP0762876A1 (fr) | Composition pharmaceutique pour prevenir et/ou traiter des infections virales, ainsi qu'eventuellement des inflammations, et utilisation de cette composition | |
| LEVENSON et al. | Influence of microorganisms on scurvy | |
| CN114891692B (zh) | 一种改善人体阴道环境的菌株及其应用 | |
| US5869446A (en) | Preparation of lactoferrin (or serotransferrin or ovotransferrin) and desferrioxamine methanesulfonate (or other low molecular weight metal ion chelators) for the therapy of viral infections | |
| JPS63501422A (ja) | 生殖器及び口腔ヘルペスの治療方法 | |
| US4271191A (en) | Method of treating hyperuricemia and gout |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |